文献速递淋巴瘤

强化免疫化疗治疗伯基特淋巴瘤真实世界结局:264例国际研究

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
PubMed 文献 · Br J Haematol · 2020-02-04

该研究基于六国回顾性淋巴瘤登记数据库,纳入264例接受强化免疫化疗的成人伯基特淋巴瘤真实世界患者。中位年龄47岁,多数为晚期且LDH升高,总缓解率89%,2年总生存率和无事件生存率分别为84%和80%。

要点

  • 成人伯基特淋巴瘤强化免疫化疗真实世界疗效优异,2年OS达84%。
  • pEFS12患者预期寿命与一般人群相似,随访应侧重生存质量。

核心结论

  • 成人伯基特淋巴瘤经强化免疫化疗后真实世界结局优异。
  • 达到pEFS12的患者复发风险低且预期寿命接近一般人群。

研究设计与样本

  • 回顾性研究,利用六国基于临床和人群的淋巴瘤登记数据库识别264例真实世界成人伯基特淋巴瘤患者。
  • 中位年龄47岁,多数为晚期疾病且LDH升高。

主要发现

  • 治疗方案包括R-CODOX-M/IVAC(47%)、R-hyper-CVAD(16%)、DA-EPOCH-R(11%)、R-BFM/GMALL(25%)和其他(2%)。
  • 总缓解率为89%,2年总生存率为84%,2年无事件生存率为80%。

临床怎么用

  • 强化免疫化疗后达到pEFS12的伯基特淋巴瘤患者复发风险低,随访策略应更关注生存者管理而非常规疾病监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0·6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95% CI: -0·7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jakobsen LH, Ellin F, Smeland KB, et al. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. Br J Haematol. 2020. PMID: 32017050. doi:10.1111/bjh.16425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。